| |
Increase in positive response with incentive
|
Cost per additional patient
|
Increase in consented patients with incentive
|
Cost per additional consented patient
|
|---|
|
Overall
|
6.9%
|
£1,549
|
5.1%
|
£1,961
|
|
FAST
|
12.0%
|
£933
|
13.1%
|
£763
|
|
SCOT
|
8.5%
|
£1,276
|
6.2%
|
£1,613
|
|
PATHWAY 1
|
−4.0%
|
N/A
|
−2.0%
|
N/A
|
|
PATHWAY 2
|
1.4%
|
£7,243
|
−4.3%
|
N/A
|
|
PATHWAY 3
|
8.7%
|
£1,249
|
4.2%
|
£2,381
|
- aFAST, Febuxostat versus Allopurinol Streamlined Trial; N/A, Not applicable; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial.
